ACSL4 and metabolic dysfunction-associated steatohepatitis: Inhibiting ACSL4 activity with rosiglitazone or knocking down its expression via siRNA reduced cellular 5-HETE levels, significantly ameliorating arsenic-induced ferroptosis and NASH (Duan et al., 2022).